Straight answers

No. Capital Genome is in active development. Every interface on this website is a concept design or illustrative preview of where the product is heading. We say this clearly because trust is the entire business.

An AI capital intelligence platform in development, designed to help businesses discover, understand and engage with institutional capital, and to help investors see qualified opportunities that genuinely fit their mandate.

No. The platform provides intelligence and connection. It does not provide investment, legal, tax or financial advice, does not arrange transactions and does not carry out regulated activities. Decisions always sit with the parties and their professional advisers.

No. All figures, investors, opportunities and results shown in concept interfaces are illustrative design content. Nothing on this website represents real clients, real transactions or real performance.

Founders and growth businesses preparing for institutional capital, investment funds and institutions who want better qualified opportunity flow, and corporates mapping capital in their sector. Early participants help shape the roadmap.

Renewable energy, green hydrogen, battery storage, data centres, AI infrastructure and MedTech, because these are the sectors where the gap between complex opportunities and specialist capital is widest.

The platform is being designed around encryption, least privilege access, audit trails and clear data governance under UK GDPR. Our Security page sets out the principles, and we welcome detailed security questions at any stage.

Use the contact page to request early access or start a conversation. Tell us which side of the table you sit on and what you would want the platform to do first.